Ombow, Yes, Cortex holds the broad Cognition / Memory use patent in the US (Europe was overturned by Lilly and Glaxo). ADHD isn't included in that patent however, due to 'prior art' (Stoll discussed this a while back in a Q+A). So other companies can freely go after ADHD, however only Cortex's low impacts are safe enough for the indication, by a wide margin. Organon licensed the Cortex-developed Org-26576, but it won't be much of a match for the latest generation Cortex low impacts like CX-1379, in potency or in patent life. So Schering will eventually need to license CX-1739 if they are serious about ADHD/Ampakines.
Cortex also holds the broad use patents for Neurotrophin Upregulation (the high impact mechanism), Schizophrenia, Respiratory related (via Univ of Alberta license), combo use with ACHase inhibitors, combo use with mGluR5 antagonists, sexual dysfunction, and some others.
Market Data 
Markets 
AI
